Press Release : Basilea shareholders approve all proposals of the board of directors at the annual general meeting

 
   Basel, Switzerland, April 21, 2021 
 
   Basilea Pharmaceutica Ltd. (SIX: BSLN) reported today that shareholders 
approved all proposals of the board of directors at today's annual 
general meeting (AGM) for the financial year 2020. 
 
   In accordance with the ordinance issued by the Swiss Federal Council 
(COVID-19 Ordinance 3, extended until December 31, 2021) and the 
protective measures against the coronavirus that currently apply, the 
board of directors of Basilea Pharmaceutica Ltd. had decided to hold the 
AGM 2021 without the physical presence of shareholders. Accordingly, 
shareholders exercised their voting rights exclusively via the 
independent proxy. At the AGM, a total of 3,997,434 shareholder votes, 
equivalent to 30.9 percent of the share capital and 53.5 percent of the 
shares entitled to vote, were represented by the independent proxy. 
 
   Domenico Scala, Chairman, commented: "We thank our shareholders for the 
broad support of the proposed motions. We regret that due to the ongoing 
coronavirus pandemic we again had to run our AGM without the physical 
presence of shareholders, but hope that we will be able to hold the AGM 
2022 under normal circumstances and again welcome our shareholders in 
person." 
 
   At the AGM, the shareholders approved the annual report, the financial 
statements and the consolidated financial statements for the financial 
year 2020. They also endorsed carrying forward the accumulated deficit 
and approved the discharge of the members of the board of directors and 
the management committee. 
 
   Domenico Scala was re-elected as Chairman and Dr. Martin Nicklasson, Dr. 
Nicole Onetto, Ronald Scott, Steven D. Skolsky and Dr. Thomas Werner 
were re-elected as members of the board of directors. In addition, Dr. 
Nicklasson and Dr. Werner were re-elected and Dr. Onetto was newly 
elected to the compensation committee. The term of all board members 
lasts until the end of the AGM 2022. 
 
   The shareholders also approved the proposed maximum aggregate amount of 
compensation for the board of directors for the period to the AGM 2022, 
and the maximum aggregate amount of compensation for the management 
committee for the financial year 2022. In a non-binding advisory vote, 
the shareholders endorsed the compensation report for the financial year 
2020. 
 
   The shareholders also approved the proposed amendment of the articles of 
association to renew the authorization of the board of directors to 
increase the share capital by a maximum of CHF 1'000'000.-- by issuing a 
maximum of 1'000'000 registered shares having a nominal value of CHF 
1.-- each until April 2023. 
 
   Finally, the shareholders re-elected Dr. Caroline Cron as independent 
proxy until the end of the next AGM and re-elected 
PricewaterhouseCoopers Ltd, Basel, as auditors for the financial year 
2021. 
 
   At the time of the AGM, 64.9 percent of the share capital were 
registered in Basilea's share register. 
 
   About Basilea 
 
   Basilea is a commercial-stage biopharmaceutical company founded in 2000 
and headquartered in Switzerland. We are committed to discovering, 
developing and commercializing innovative drugs to meet the medical 
needs of patients with cancer and infectious diseases. We have 
successfully launched two hospital brands, Cresemba for the treatment of 
invasive fungal infections and Zevtera for the treatment of severe 
bacterial infections. We are conducting clinical studies with two 
targeted drug candidates for the treatment of a range of cancers and 
have a number of preclinical assets in both cancer and infectious 
diseases in our portfolio. Basilea is listed on the SIX Swiss Exchange 
(SIX: BSLN). Please visit basilea.com. 
 
   Disclaimer 
 
   This communication expressly or implicitly contains certain 
forward-looking statements, such as "believe", "assume", "expect", 
"forecast", "project", "may", "could", "might", "will" or similar 
expressions concerning Basilea Pharmaceutica Ltd. and its business, 
including with respect to the progress, timing and completion of 
research, development and clinical studies for product candidates. Such 
statements involve certain known and unknown risks, uncertainties and 
other factors, which could cause the actual results, financial condition, 
performance or achievements of Basilea Pharmaceutica Ltd. to be 
materially different from any future results, performance or 
achievements expressed or implied by such forward-looking statements. 
Basilea Pharmaceutica Ltd. is providing this communication as of this 
date and does not undertake to update any forward-looking statements 
contained herein as a result of new information, future events or 
otherwise. 
 
   For further information, please contact: 
 
 
 
 
  Peer Nils Schröder, PhD 
   Head of Corporate Communications & Investor Relations 
  Phone                                                            [phone] 
  E-mail     mailto:[e-mail] [e-mail] 
              mailto:[e-mail] [e-mail] 
           ----------------------------------------------------------------------- 
 
 
   This press release can be downloaded from www.basilea.com. 
 
   Attachment 
 
 
   -- Press release (PDF) 
      https://ml-eu.globenewswire.com/Resource/Download/07ba6baf-8182-489e-b799-5ac423710cfc

(END) Dow Jones Newswires

April 21, 2021 13:53 ET (17:53 GMT)